ROCKWELL MEDICAL, INC. Debt Securities, Available-for-sale, Unrealized Loss
ROCKWELL MEDICAL, INC. (RMTI) reported Debt Securities, Available-for-sale, Unrealized Loss of $611 for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2019-11-12
- ROCKWELL MEDICAL, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2019-09-30 was -$2.19K, a 101.39% decline year-over-year.
- ROCKWELL MEDICAL, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2019-06-30 was $2.75K, a 98.07% decline year-over-year.
- ROCKWELL MEDICAL, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2019-03-31 was $49.00.
- ROCKWELL MEDICAL, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2018-12-31 was $1.19K.
- ROCKWELL MEDICAL, INC. debt securities, available-for-sale, unrealized loss for fiscal 2017 was $65.90K, a 92.69% decline from fiscal 2016.
- ROCKWELL MEDICAL, INC. debt securities, available-for-sale, unrealized loss for fiscal 2016 was $901.88K, a 8.47% decline from fiscal 2015.
- ROCKWELL MEDICAL, INC. debt securities, available-for-sale, unrealized loss for fiscal 2015 was $985.37K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month as first filed |
|---|---|---|---|---|---|
| 2019-09-30 | -$2.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $562.00 derived: sum of 2 quarters · filed 2019-11-12 | $611.00 10-Q · filed 2019-11-12 | $1.80K derived: sum of 4 quarters · filed 2019-11-12 | |
| 2019-06-30 | $2.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $2.80K 10-Q · filed 2019-08-09 | $3.99K derived: sum of 3 quarters · filed 2019-11-12 | $161.97K derived: sum of 4 quarters · filed 2019-11-12 | |
| 2019-03-31 | $49.00 10-Q · filed 2019-05-10 | $1.24K derived: sum of 2 quarters · filed 2019-11-12 | $159.22K derived: sum of 3 quarters · filed 2019-11-12 | $301.68K derived: sum of 4 quarters · filed 2019-11-12 | |
| 2018-12-31 | $1.19K derived: 10-Q 12 month − 10-Q 9 month · filed 2019-11-12 | $159.17K derived: sum of 2 quarters · filed 2019-11-12 | $301.63K derived: sum of 3 quarters · filed 2019-11-12 | $1.19K 10-Q · filed 2019-11-12 | |
| 2018-09-30 | $157.98K 10-Q · filed 2018-11-09 | $300.44K derived: sum of 2 quarters · filed 2018-11-09 | $0.00 10-Q · filed 2018-11-09 | ||
| 2018-06-30 | $142.45K 10-Q · filed 2018-08-14 | $151.06K 10-Q · filed 2018-08-14 | |||
| 2017-12-31 | -$10.49K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$10.49K derived: sum of 2 quarters · filed 2019-03-18 | $65.90K 10-K · filed 2019-03-18 | $901.88K 10-K · filed 2018-03-15 | |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-09 | $76.40K 10-Q · filed 2018-11-09 | |||
| 2016-12-31 | $901.88K 10-K · filed 2017-03-15 | ||||
| 2015-12-31 | $985.37K 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B |